Lantheus (LNTH) AI Stock Analysis

• Market Cap: $4.88B
• Dividend Yield: N/A
• Average Volume (3M): 717.75K
• Price to Earnings (P/E): 31.8
• Beta (1Y): 0.59
• Revenue Growth: 1.95%
• EPS Growth: -60.40%
• Country: US
• Employees: 808
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.67
• Shares Outstanding: 66,311,775
• 10 Day Avg. Volume: 729,818
• 30 Day Avg. Volume: 717,745
• PEG Ratio: -3.52
• Price to Book (P/B): 5.69
• Price to Sales (P/S): 4.04
• P/FCF Ratio: 12.55
• Enterprise Value/Market Cap: 1.10
• Enterprise Value/Revenue: 3.49
• Enterprise Value/Gross Profit: 5.72
• Enterprise Value/Ebitda: 14.08
• 1Y Price Target: $79.25
• Price Target Upside: 4.66% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): 5.51
• Revenue Forecast (FY): $1.49B

• Rating: 69 Neutral
• Price Target: $83.00 ▲(9.61% Upside)
• Action: Downgraded Date: 02/26/26
• Date: Action: Downgraded 02/26/26

The score is driven primarily by solid multi-year financial performance and an established uptrend, but it is held back by recent TTM margin/cash-flow weakening, very stretched momentum signals (RSI/Stoch), and a relatively high P/E. Earnings-call commentary supports medium-term catalysts and guidance, but near-term pressures in PYLARIFY pricing/margins and operating income reduce confidence.

Positive Factors

Robust revenue growth & healthy margins

Sustained high revenue growth and strong gross/net margins indicate durable demand for Lantheus's imaging agents and efficient operations. This profitability supports ongoing R&D, commercial expansion, and reinvestment, underpinning long-term product development and competitive positioning.

Improved leverage and high ROE

A lower debt-to-equity and a high return on equity reflect stronger leverage management and effective capital allocation. This balanced capital structure enhances financial flexibility for funding pipeline development and acquisitions without overly stressing refinancing risk over the medium term.

Diversified pipeline and strategic M&A

Strategic acquisitions and a growing radiopharma pipeline, including MK-6240 toward a 2026 PDUFA, materially diversify revenue exposure beyond Pylarify. Success would extend addressable markets (Alzheimer's imaging) and strengthen vertical capabilities, supporting durable growth and higher recurring revenues.

Negative Factors

Declining PYLARIFY sales

PYLARIFY remains a revenue driver; a persistent sales decline and competitive pressures reduce top-line resilience and increase execution risk. Slower growth or pricing erosion in the flagship product can impair funding for R&D and acquisitions, and heighten reliance on pipeline approvals for lasting growth.

Margin compression and operating income decline

Material margin compression and a ~27.6% drop in operating income reflect structural pricing and integration pressures from acquisitions and product mix shifts. If sustained, lower margins will constrain free cash for investment and reduce profitability resilience against competitive or reimbursement changes.

Declining free cash flow and remaining debt risk

A meaningful FCF decline reduces internal funding capacity for R&D, commercialization, and debt paydown. Coupled with noted total debt levels, weaker FCF could pressure liquidity or force dilutive financing, limiting strategic optionality and increasing financial risk over the medium term.

Lantheus Business Overview & Revenue Model

Company Description

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.

How the Company Makes Money

Lantheus generates revenue primarily through the sale of its diagnostic imaging agents and radiopharmaceuticals. The company's revenue model is based on direct sales to hospitals, imaging centers, and other healthcare providers. Key revenue streams include the sales of Pylarify and other established imaging products, as well as potential royalties from partnerships and collaborations with other pharmaceutical companies. Significant partnerships, such as agreements with healthcare institutions and alliances with research organizations, enhance its market reach and contribute to the company's earnings. Additionally, Lantheus may benefit from expanding its product pipeline through research and development, leading to new launches that can further increase revenue.

Lantheus Financial Statement Overview

Summary

Multi-year fundamentals remain solid (strong revenue growth since 2020, shift from losses to sustained profitability, improved leverage, and strong absolute operating/free cash flow). However, the latest TTM shows flattening growth plus sharp margin and cash-flow softening versus 2024, which tempers the overall strength.

Income Statement

LNTH has delivered strong top-line expansion over the last several years (revenue rising materially from 2020 through 2024), but growth has largely flattened in TTM (Trailing-Twelve-Months) versus 2024. Profitability is a clear strength versus its earlier history—moving from losses in 2020–2021 to solid profits from 2022 onward—though margins have compressed sharply in TTM (Trailing-Twelve-Months) versus 2024 (notably lower operating and net margins). Overall, the business shows a strong multi-year turnaround and scale-up, but the latest period signals decelerating growth and weaker profitability.

Balance Sheet

The balance sheet looks healthier versus prior years, with leverage trending down from elevated levels in 2022 to a more moderate debt load relative to equity in 2023–TTM (Trailing-Twelve-Months). Equity has expanded meaningfully since 2022, supporting a larger asset base. Return on equity remains positive and solid in TTM (Trailing-Twelve-Months), but it has cooled versus 2023–2024 alongside the margin compression, which is the main watch item. Overall leverage appears manageable, with improving capital structure over time.

Cash Flow

Cash generation is a key positive: operating cash flow and free cash flow are strong in absolute dollars in TTM (Trailing-Twelve-Months), and free cash flow remains closely aligned with reported earnings. However, cash flow momentum has softened recently—free cash flow declined in TTM (Trailing-Twelve-Months) versus 2024, and operating cash flow relative to earnings also stepped down from the prior year. The company still demonstrates good cash conversion, but the near-term trend is weaker than the strong 2023–2024 run-rate.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.54B	1.53B	1.30B	935.06M	425.21M	339.41M
Gross Profit	941.95M	988.29M	709.54M	581.70M	187.69M	138.76M
EBITDA	382.55M	515.27M	491.00M	81.83M	-25.00M	22.69M
Net Income	233.56M	312.44M	326.66M	28.07M	-71.28M	-13.47M
Balance Sheet
Total Assets	2.23B	1.98B	1.65B	1.32B	863.78M	869.82M
Cash, Cash Equivalents and Short-Term Investments	359.12M	912.81M	713.66M	415.65M	98.51M	79.61M
Total Debt	738.00K	619.44M	616.95M	583.51M	191.31M	235.90M
Total Liabilities	1.14B	892.33M	835.26M	874.11M	399.35M	355.62M
Stockholders Equity	1.09B	1.09B	815.89M	447.15M	464.44M	514.21M
Cash Flow
Free Cash Flow	348.64M	493.13M	258.70M	263.43M	41.78M	3.92M
Operating Cash Flow	390.14M	544.75M	305.26M	281.78M	53.92M	16.40M
Investing Cash Flow	-627.17M	-226.01M	5.94M	-276.55M	3.68M	-4.91M
Financing Cash Flow	-316.58M	-118.54M	-13.06M	311.69M	-39.33M	-21.86M

Lantheus Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 75.72
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LNTH, the sentiment is Positive. The current price of 75.72 is above the 20-day moving average (MA) of 69.00, above the 50-day MA of 67.71, and above the 200-day MA of 65.02, indicating a bullish trend. The MACD of 2.23 indicates Negative momentum. The RSI at 79.23 is Negative, neither overbought nor oversold. The STOCH value of 91.57 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LNTH.

Lantheus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LNTH	69 Neutral	$4.88B	31.80	14.59%	―	1.95%	-60.40%
ANIP	66 Neutral	$1.72B	46.79	7.83%	―	48.87%	―
AMRX	64 Neutral	$4.61B	1,026.76	―	―	9.50%	―
SUPN	55 Neutral	$3.06B	-82.35	-1.86%	―	4.54%	-130.59%
HCM	52 Neutral	$2.59B	5.65	47.54%	―	-1.35%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PRGO	49 Neutral	$2.01B	-38.25	-0.65%	8.48%	-2.55%	66.00%